Bayer's Retinal Pioneers Programme
Access resources developed in collaboration with thought leaders in ophthalmology
Established in 2018, Retinal Pioneers is a promotional programme organised and funded by Bayer, designed to contribute towards the evolution of retinal knowledge and catalyse innovation in medical retina. As part of the programme, this Retinal Pioneers Hub provides a source of
Retinal Pioneers Summit (RPS)
Retinal Pioneers Summit is an annual meeting designed to enable UK ophthalmologists to explore the latest innovations and scientific and clinical advancements in the management of medical retina conditions. Please see below the 2025 highlights video to find out more about this meeting.
Prescribing information for EYLEA® (aflibercept)
Key developments relating to EYLEA (aflibercept) 8 mg
In this video, Kirsty discusses current challenges in medical retina services in Scotland and provides insights into the implementation, outcomes, practical considerations and overall impact of using EYLEA 8 mg in treating patients with nAMD.
Prescribing information for EYLEA® (aflibercept)
Bitesize OCT knowledge checkers
Test your knowledge of OCT disease biomarkers in this series of OCT images and associated knowledge-checker questions provided by
Challenging cases in medical retina
These case study posters feature challenging scenarios across multiple indications in medical retina, provided by a range of clinicians from across the UK. Each poster includes key information from one or two short case studies and invites you to reflect on the steps that you would follow to manage the same cases.
Challenging cases in medical retina: A UK case study
DMO, diabetic macular oedema. HCP, healthcare professional. nAMD, neovascular age-related macular degeneration. NHS, National Health Service. OCT, optical coherence tomography. RVO, retinal vein occlusion.
EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular oedema (DMO) and visual impairment due to macular oedema secondary to retinal vein occlusion (branch, central and hemiretinal RVO). For full details please refer to Summary of Product Characteristics.
Prescribing information for EYLEA® (aflibercept)
PP-EYL-GB-3102 | March 2026